Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Karyopharm Therapeutics Inc clinical trials
The registry lists 37 studies whose lead sponsor is Karyopharm Therapeutics Inc. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 9, 2026.
Keep track of what changes. Save the Karyopharm Therapeutics Inc studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Karyopharm Therapeutics Inc.
- Karyopharm Therapeutics Inc37 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 37 of 37.
- A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.RecruitingNCT04414475Phase 2
- Selinexor and Backbone Treatments of Multiple Myeloma PatientsRecruitingNCT02343042Phase 1/2
- Karyopharm Expanded Access Program for SelinexorAvailableNCT07215832
- A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate ThrombocytopeniaRecruitingNCT05980806Phase 2
- Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination TreatmentCompletedNCT04256707Phase 1/2
- A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaActive, not recruitingNCT04442022Phase 2/3
- Study of Selinexor in Combination With Ruxolitinib in MyelofibrosisActive, not recruitingNCT04562389Phase 3
- Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Active, not recruitingNCT02227251Phase 2
- Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial CarcinomaActive, not recruitingNCT05611931Phase 3
- A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated MyelofibrosisActive, not recruitingNCT04562870Phase 2
- Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]CompletedNCT03555422Phase 3
- Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)WithdrawnNCT04607772Phase 1/2
- Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer IndicationsCompletedNCT02649790Phase 1/2
- A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent GlioblastomaTerminatedNCT04421378Phase 1/2
- PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)TerminatedNCT02702492Phase 1
- Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced MelanomaTerminatedNCT04768881Phase 2
- Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple MyelomaCompletedNCT03110562Phase 3
- A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With SarcomaCompletedNCT01896505Phase 1
- A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS MutationsTerminatedNCT04854434Phase 2
- Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological CancerCompletedNCT01607892Phase 1
- Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple MyelomaWithdrawnNCT02628704Phase 2
- Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent GliomasTerminatedNCT01986348Phase 2
- Selinexor in Initial or Refractory and/or Relapsed Richter's TransformationTerminatedNCT02138786Phase 2
- Selinexor (KPT-330) in Older Patients With Relapsed AMLCompletedNCT02088541Phase 2
- Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma PatientsWithdrawnNCT02389543Phase 1/2
- Selinexor Treatment of Refractory MyelomaCompletedNCT02336815Phase 2
- Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor CancerCompletedNCT01607905Phase 1
- Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell LymphomaTerminatedNCT02314247Phase 2
- Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell CarcinomasTerminatedNCT02213133Phase 2
- SHIP (Selinexor in Hormone Insensitive Prostate Cancer)TerminatedNCT02146833Phase 2
- Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome PatientsWithdrawnNCT02431351Phase 2
- Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic MalignanciesCompletedNCT02025985Phase 2
- Selinexor in Advanced LiposarcomaCompletedNCT02606461Phase 2/3
- Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19WithdrawnNCT04355676Phase 2
- Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy AdultsTerminatedNCT02431364Phase 1
- Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) PatientsWithdrawnNCT02367690Phase 1/2
- Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 InfectionCompletedNCT04349098Phase 2